Amphastar Pharmaceuticals
✦ Quant Fair Value how this is computed
- Implied fair-value range of 20.86-51.14, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -21.5% below the average-multiple fair value of 36.00.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Amphastar Pharmaceuticals (AMPH) | 1.20B | 12.96 | 1.48 | 0.00% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 25.1% below Morningstar's fair value estimate.
Fair value
Amphastar Pharmaceuticals Inc receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 17% discount to our quantitative fair value estimate of $35.33 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's profitability strengthens our estimated valuation. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 9.2%, which falls in the top 30% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.
Alternatively, the company's balance sheet is potentially concerning. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. The firm's current ratio of 3.3, for example, sits in the top 30% globally. This suggests that management of working capital may be "lazy", tying up valuable capital that could be considered excessive and leading to a lower return on invested capital. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.
Amphastar Pharmaceuticals discussion 0 comments